Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25926715
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Role of biologics in intractable urticaria
#MMPMID25926715
Cooke A
; Bulkhi A
; Casale TB
Biologics
2015[]; 9
(?): 25-33
PMID25926715
show ga
Chronic urticaria (CU) is a common condition faced by many clinicians. CU has
been estimated to affect approximately 0.5%-1% of the population, with nearly 20%
of sufferers remaining symptomatic 20 years after onset. Antihistamines are the
first-line therapy for CU. Unfortunately, nearly half of these patients will fail
this first-line therapy and require other medication, including immune response
modifiers or biologics. Recent advances in our understanding of urticarial
disorders have led to more targeted therapeutic options for CU and other
urticarial diseases. The specific biologic agents most investigated for
antihistamine-refractory CU are omalizumab, rituximab, and intravenous
immunoglobulin (IVIG). Of these, the anti-IgE monoclonal antibody omalizumab is
the best studied, and has recently been approved for the management of CU. Other
agents, such as interleukin-1 inhibitors, have proved beneficial for Schnitzler
syndrome and cryopyrin-associated periodic syndromes (CAPS), diseases associated
with urticaria. This review summarizes the relevant data regarding the efficacy
of biologics in antihistamine-refractory CU.
free
free
free
